Introduction Proton pump inhibitors (PPIs) have been implicated in the occurrence of moderate to severe myopathies in several case reports. Aim This study was performed to assess the reporting risk of muscular adverse drug reactions (ADRs) associated with PPIs in the Italian National Network of Pharmacovigilance database. Methods A disproportionality analysis (case/non-case) was performed using spontaneous reports collected in the database between July 1983 and May 2016. Reporting odds ratio (ROR) and 95% confidence intervals (CIs) were calculated as a measure of disproportionality. In a secondary and tertiary analysis, we explored the association of PPIs with muscular ADRs after taking into account the masking effect of statins. Moreover, the possibility of an interaction between PPIs and statins, leading to the occurrence of muscular ADRs, was also tested.
Introduction
Myopathy has been defined as any muscular disorder, ranging from mild clinical manifestations, including muscle pain, tenderness, weakness and cramps (with or without elevations of creatine phosphokinase [CPK] in the serum), up to more severe conditions, such as rhabdomyolysis [1, 2] . Myopathy results usually from intense physical activity or traumatic events, but it may occur also as a consequence of exposure to chemicals and drugs, particularly alcohol and 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) [3] . After cerivastatin marketing withdrawal in 2001 due to fatal cases of rhabdomyolysis, which occurred up to 80 times more frequently with cerivastatin than any other statin [4] , myopathies have become a major concern in the development of new drugs. Furthermore, the case of cerivastatin, amplified by the mass media due to publicity surrounding the withdrawal, promoted a general increase in adverse drug reaction (ADR) reporting, especially for musculoskeletal ADRs, which persisted in the following years [5, 6] . Notably, assuming that musculoskeletal disorders like rhabdomyolysis associated with statins are currently well known and described in literature [7] , awareness about this safety issue has progressively increased over the years and it is plausible to hypothesize that when a case of myopathy occurs in clinical practice, statins are one of the first suspected potential causes considered.
Besides statins, several case reports [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and an important case series published by the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre-UMC) [23] generated the hypothesis that the use of proton pump inhibitors (PPIs) can also be associated with myopathies.
Notably, muscular adverse effects such as cramps or muscle aches, muscular weakness and myalgia are currently labelled as rare events for the overall class of PPIs, while rhabdomyolysis has been included by the Food and Drug Administration (FDA) in the Summary of Product Characteristics (SPC) of pantoprazole and rabeprazole only, and reported as ''an adverse event identified during post-approval use'' [24, 25] . Interestingly, rhabdomyolysis has been reported as listed by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in the SPC of omeprazole and rabeprazole, and more recently the Ministry of Health, Labour and Welfare and Japan PMDA have announced that the package insert for esomeprazole will be revised to include risk of rhabdomyolysis as a clinically significant adverse reaction [25, 26] . However, rhabdomyolysis is not described in the SPC for any PPI in several European countries including the UK [27] and Italy [24] .
To the best of our knowledge, studies designed specifically to investigate, with a method of disproportionality, a potential signal of risk of muscular ADRs with PPIs are lacking. Furthermore, provided that PPIs are associated with muscular ADRs, their possible interaction with statins could be hypothesized with a consequent enhancement of the overall risk of drug-induced muscle injuries in patients receiving a PPI-statin combination. At present, the only available evidence supporting this putative interaction stems from sporadic case reports [28] [29] [30] [31] [32] .
Based on the above background, the primary aim of the present study was to perform a disproportionality analysis using the Italian National Network of Pharmacovigilance (Rete Nazionale di Farmacovigilanza-RNF) database to strengthen the signal, currently assessed with a qualitative approach only, for the association of PPIs with muscular ADRs, including rhabdomyolysis as a distinct preferred term (PT). The secondary aims were to explore whether the signal can be differential among specific PPIs, and whether PPI-statin combinations can be associated with a higher reporting risk of muscular adverse reactions rather than any other ADR as compared with statins alone.
Methods

Data Source
The present case/non-case analysis was performed using the RNF database of the Italian Medicines Agency (Agenzia Italiana del Farmaco-AIFA). This database contains suspected ADRs reported in Italy since July 1, 1983 . Physicians represent the most frequent source for reports (over 90%), while the remaining reporters include pharmacists, nurses, other healthcare professionals and patients. The Medical Dictionary for Regulatory Activities (MedDRA Ò ) is used to codify the ADRs [33] . Attribution of causality assessment (Naranjo probability scale) [34] and monitoring of quality of reports are performed by the Italian Regional Centers of Pharmacovigilance. Of note, in 2014 Italy was one of the major contributors to the WHO Programme for International Drug Monitoring, with reports of higher quality compared with the other countries participating in the programme [35] .
Selection Criteria
This study included all reports recorded in the RNF database from July 1, 1983 to May 31, 2016. All reports coming from published case reports and reports of adverse event following immunization (AEFI) were excluded from the analysis. Reports containing cerivastatin as the suspected drug were also excluded since cerivastatin was withdrawn from the market in 2001 due to its association with severe muscular ADRs [4] . Low-quality reports, defined as reports with missing data (event date, age and gender of patient) were excluded [36] . In addition, we excluded duplicate reports, removing the older ones by sorting case identification numbers. Potential duplicates were identified using the following report fields: date of ADR occurrence, suspected drugs, patient initials, age and gender. The duplicates were identified when all record fields listed above were matched between two or more reports. Potential duplicates of reports of muscular ADR were reviewed case by case to avoid the elimination of non-duplicated cases.
Cases Definition
Cases were defined using two different approaches to cover a range of sensitivity and specificity. For the sensitive approach, we included all reports with at least one MedDRA Ò PT of muscular ADR. On the basis of previous analysis [23] , we expanded the list of PTs indicating muscular ADRs as follows: 'biopsy muscle abnormal'; 'blood creatine phosphokinase abnormal'; 'blood creatine phosphokinase increased'; 'blood creatine phosphokinase MM increased'; 'mitochondrial myopathy'; 'muscle disorder'; 'muscle enzyme increased'; 'muscle fatigue'; 'muscle injury'; 'muscle necrosis'; 'muscle rupture'; 'muscle swelling'; 'muscular weakness'; 'musculoskeletal injury'; 'myalgia'; 'myalgia intercostal'; 'myopathy'; 'myopathy toxic'; 'myositis'; 'myositis-like syndrome'; 'necrotizing myositis'; 'polymyositis'; and 'rhabdomyolysis'. Non-cases (controls) were defined by reports including all MedDRA Ò PTs with the exception of those listed above. For the specific approach, cases included all reports containing the MedDRA Ò PT 'rhabdomyolysis'. Non-cases included all other reports in the database.
Notably, reports containing more than one event meeting criteria listed above were not over-counted; analysis was performed at the case level and not at the event level.
Index and Reference Groups Definition
Index reports included all reports in which at least one PPI (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole) or its fixed-dose combination with other drugs was reported as the suspected causative drug. The reference group included all other reports.
Statistical Analysis
Descriptive statistics were used to summarize the characteristics of reports across comparison groups: Wald Chi square test (gender and thyroid dysfunction); Student's t test (age); Mann-Whitney U test (number of drugs).
The use of medications for thyroid diseases (ATC code beginning with H03A and H03B) among concomitant drugs was used as a proxy of thyroid dysfunction, since it can be a risk factor for muscular adverse events [37] [38] [39] . Unfortunately, other variables that could be of interest as risk factors for muscular adverse events are not assessable from spontaneous ADRs reports. A p-value \ 0.05 was considered to be statistically significant.
In the primary analysis, the association of PPIs with muscular ADRs was tested by the case/non-case methodology, calculating the reporting odds ratio (ROR) and 95% confidence intervals (CIs) as a measure of disproportionality. ROR compares the frequency of an adverse event reported for a particular drug with the frequency of reports of the same reaction for the reference group [40] [41] [42] . For the ROR, an association was formally defined when the number of cases was three or more and the lower limit of the 95% two-sided confidence interval was [1 [43] . Therefore, when cases were fewer than three, RORs were not calculated.
RORs were calculated by logistic regression with age and gender as predictors. Reports containing at least one PPI as the suspected drug were compared with the reference group to assess the RORs for the muscular ADRs group and the PT rhabdomyolysis. Furthermore, we explored the possibility of drug-specific effects in a subanalysis where RORs were calculated using single PPIs as index groups. Correction for multiple testing was considered but not performed given the very small size of p values.
Unmasking Strategy: Secondary and Tertiary Analyses
In signal detection analysis, the masking effect has been defined as the condition that occurs when an signal of disproportionate reporting (SDR) [44, 45] for a given drugevent pair might be hidden by the presence of another product in the same database with a high number of reports for the event of interest [46] . Actually, masking may also be defined in terms of suppressing measures of SDR regardless of whether an SDR is initially present. In other words, masking can conceal SDRs, but existing SDRs may increase in magnitude as a result of unmasking as well [47] . In this respect, the large number of reports of statinassociated muscular ADRs in the database could likely mask any SDR for muscular ADRs or rhabdomyolysis associated with other drugs. Furthermore, since cerivastatin withdrawal, statins are always considered as a primary causative factor in the case of muscular adverse events, while the potential role of other drugs (including PPIs) is likely underestimated [2] . Indeed, in clinical practice, PPIinduced muscular injuries are likely underdiagnosed or misdiagnosed due to low suspicion (infrequent occurrence, limited dissemination of information) and uncertain clinical presentation [48] . Therefore, it is fairly conceivable that in a circumstance where a patient develops a muscular ADR, during a concomitant treatment with PPIs and statins, healthcare professionals are more prone to report the statin, known to be associated with myopathies [49] [50] [51] , as the only suspected drug, thus classifying the PPI as a concomitant drug, even ignoring case-specific features such as a plausible temporal relationship for the PPI. Based on the above considerations, in the secondary analysis, we explored the association of PPIs and muscular injury after excluding the putative masking effect of statins. This 'unmasking' was obtained by repeating the primary analysis after excluding from the dataset all reports in which at least one statin (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and their fixed-dose combinations with other drugs) was suspected of being the causative drug [52] . Accordingly, reports in which a PPI and a statin were considered cosuspected were also excluded from the analysis.
To achieve a further unmasking effect and to explore whether the PPI-statin combination can be associated with a higher ROR of muscular ADRs compared with statins alone, we performed a tertiary analysis in which muscular ADRs (cases) were considered as potentially associated with the drugs of interest (PPIs or statins in this analysis), regardless of whether the initial reporter classified a drug as suspected or concomitant. This approach should allow us to overcome the eventual problem of misrecognition of PPIs as potential causative agents of muscular ADRs. Index reports were classified into three different categories: (i) reports containing at least one PPI but not a statin; (ii) reports containing at least one PPI-statin combination; and (iii) reports containing at least one statin but not a PPI. The reference group included all reports containing neither PPIs nor statins. In this analysis, reports containing cerivastatin classified as a suspected or concomitant drug were excluded.
Reports containing at least one PPI but not a statin were compared with the reference group to assess the RORs for muscular ADRs and rhabdomyolysis. Since muscular ADRs may not necessarily be a class effect of PPIs, we explored the possibility of a drug-specific effect in a subanalysis where RORs were calculated using single PPIs as index groups.
Finally, we assessed the RORs for the PPIs-statins group and the statins group, and according to Yue et al. [36] , we considered a 'plausible' signal of risk for a positive interaction when the ROR value for the PPIs-statins pair was higher than that reported for the statins group, without overlapping of values of CIs (95%). A further subanalysis was conducted using single PPI-statin pairs and statins as index groups to explore the possibility of specific drug-drug interactions.
Sensitivity Analyses
When exposure was classified by drug classes, in addition to age and sex, two additional predictors were considered (number of drugs and thyroid dysfunction) in two sensitivity analyses. Since these two variables can be collinear, we have checked that the width of confidence intervals was not suggestive of collinearity. RORs were calculated by logistic regression with age, gender, number of drugs, and age, gender, thyroid dysfunction, as predictors, separately. To avoid model instability, the effect of these two covariates was calculated in principal analyses where index groups were based on drug classes.
Statistical analysis was performed using the Statistical Package for the Social Science (SPSS) version 20.0 for Windows (IBM Corporation, Armonk, NY, USA).
Results
A total of 358,014 spontaneous reports of suspected ADRs were collected from July 1, 1983 to May 31, 2016 in the RNF database. After considering inclusion and exclusion criteria, the final dataset included 274,108 reports ( Fig. 1 ).
Muscular Adverse Drug Reactions (Group
Term Including Rhabdomyolysis)
Primary Analysis
In this analysis, 3403 reports included at least one PPI as the suspected drug, compared with 270,705 reports in the reference group. When the reports containing at least one PPI as the suspected drug were considered for the primary analysis (Table 2) , we found 97 events corresponding to our definition of muscular ADR distributed in 92 reports (cases).
Detailed information on the characteristics of these reports are provided in Supplementary File 1 and Supplementary  Table 2 (see ESM) .
Crude and adjusted RORs (95% CI) for the occurrence of muscular ADRs with at least one PPI reported as the suspected drug in the primary analysis are displayed in Fig. 1 In the sensitivity analyses, neither the number of drugs nor the presence of thyroid dysfunction changed the RORs substantially and these remained statistically significant. When single PPIs were analyzed as index groups (Table 3) , the drug most frequently involved in cases of muscular ADRs was esomeprazole (32), followed by omeprazole (19) , lansoprazole (18) , pantoprazole (14) and rabeprazole (9) . The RORs of muscular ADRs, adjusted for age and gender, were significant for esomeprazole (adjusted ROR 2.559, 95% CI 1.793-3.653; p \ 0.001) and rabeprazole (adjusted ROR 2.432, 95% CI 1.246-4.747; p \ 0.01).
Secondary Analysis
A total of 268,240 reports were included after the exclusion of 5868 cases reporting at least one statin as the suspected drug, aiming at evaluating the eventual size of masking effect of statins (Fig. 1) . The main characteristics of the study population for secondary analysis and stratified for single PPIs are displayed in Supplementary Tables 3 and 4 , respectively (see ESM).
After unmasking by excluding statin reports from the analysis, crude and adjusted RORs (95% CI) for the occurrence of muscular ADRs in the PPIs group increased by almost 100% compared with the primary analysis ( Table 2 ). The ROR for muscular ADRs, adjusted for age and gender, was 3.038 (95% CI 2.446-3.774; p \ 0.001). When the numbers of drugs and thyroid dysfunction were introduced as covariates in the model, no substantial changes in ROR point estimates and 95% CIs were observed. When single PPIs were analyzed as index groups, RORs of muscular ADRs, adjusted for age and gender, were significant for omeprazole, lansoprazole and pantoprazole in addition to esomeprazole and rabeprazole, identified in the primary analysis (Table 3) .
Tertiary Analysis
When PPIs and statins were considered, disregarding their roles (suspected or concomitant), a total of 274,104 reports were analyzed, with 23,998 reports classified in the PPIs but not statins group, 7272 in the combination PPIs-statins group, 14,398 in the statins but not PPIs group, and 228,436 reports in the reference group (neither PPIs nor statins) (Fig. 1) .
Supplementary Table 5 (see ESM) summarizes the main features of the population (age, gender, number of drugs and thyroid dysfunction) stratified by index (PPIs no statins, PPIs-statins, statins no PPIs) and reference (no PPIs, no statins) groups. A statistically significant difference was detected among groups for all covariates (p \ 0.001). The Tables 6a-f (see ESM) . No cases of ADRs (muscular or others) associated with pitavastatin were recorded in the RNF during the study period, while only two cases reported dexlansoprazole as a concomitant drug and in one of these cases CPK increase was described. Owing to the limited number of cases related to dexlansoprazole, this drug was not included in the specific sub-analysis on single PPIs.
When reports containing PPIs only (no statins) were considered, we found 290 muscular events in 277 reports (cases) ( Table 2) . Detailed information on characteristics of the reports are provided in Supplementary File 2 and Supplementary Table 7 (see ESM) .
Crude and adjusted RORs (95% CI) for muscular ADRs in the PPIs (no statins) group are displayed in Table 2 . The ROR for muscular ADRs, adjusted for age and gender, was 1.374 (95% CI 1.208-1.563; p \ 0.001). When RORs were adjusted also for the number of drugs and thyroid dysfunction, we observed no substantial changes in the point estimates and 95% CI.
When single PPIs (no statins) were analyzed as index groups (Table 3) , the PPI mostly reported as the suspected or concomitant drug was omeprazole (75 cases), followed by pantoprazole (63), lansoprazole (62), esomeprazole (61) and rabeprazole (18 The results of the sub-analysis conducted using single PPI-statin combination and single statin as index groups are displayed in Supplementary Table 9 . Notably, no combination resulted in a higher ROR for muscular ADRs when compared with the respective statin alone.
Rhabdomyolysis
Primary Analysis
In the primary analysis, including reports with at least one PPI reported as suspected, five cases of rhabdomyolysis were identified. The main characteristics of these cases are shown in Supplementary Table 10 (see ESM) . PPIs implicated in cases of rhabdomyolysis were omeprazole (two cases), lansoprazole (two cases) and esomeprazole (one case). In four cases, other co-suspected drugs were reported: (i) glyburide/metformin; (ii) hydroxychloroquine; (iii) olmesartan/hydrochlorothiazide and simvastatin; and (iv) febuxostat, repaglinide, and voriconazole. Rhabdomyolysis occurred from 3 days up to 3 years after starting the therapy with PPI. Table 5 shows the RORs for the occurrence of rhabdomyolysis in the primary analysis, and Supplementary Table 11 shows the RORs for single PPIs (see ESM) . Notably, in these analyses the RORs were not statistically significant.
Secondary Analysis
After exclusion of reports with at least one statin reported as suspected, only four cases of rhabdomyolysis were identified in the secondary analysis, and no RORs were statistically significant (Table 5 and Supplementary  Table 11 [see ESM]).
Tertiary Analysis
When reports containing PPIs only were considered, regardless of their role (suspect or concomitant), 38 cases of rhabdomyolysis were detected (Table 5 ). At least one PPI was classified as the suspected drug in four reports. In the 34 reports of rhabdomyolysis where PPIs were reported as concomitant drugs, the drugs most frequently reported as suspected, for which rhabdomyolysis is a labelled reaction [24, 25] , were bezafibrate (4), fenofibrate (4), colchicine (3), olanzapine (3) and levofloxacin (2) .
Crude and adjusted RORs (95% CI) for the combination PPIs (no statins) group and rhabdomyolysis are shown in Table 5 . The ROR, adjusted for age and gender, of rhabdomyolysis was: 1.667 (95% CI 1.173-2.369; p \ 0.01). When ROR was adjusted for age, gender and thyroid dysfunction, we did not observe substantial changes in point estimates and 95% CI. When considering RORs adjusted for age, gender and number of drugs, the statistical significance was not maintained (adjusted ROR 0.817, 95% CI 0.542-1.233; p \ 0.01). Time to event onset for PPIs (no statins) group was described in only ten reports (see Supplementary Table 12, ESM) .
When specific PPIs were used as index groups (Supplementary Table 11 , see ESM), RORs of rhabdomyolysis, adjusted for age and gender, were statistically significant only for lansoprazole (adjusted ROR 2.050, 95% CI 1.140-3.688; p \ 0.05) and omeprazole (adjusted ROR 2.142, 95% CI 1.244-3.690; p \ 0.01). When considering reports with at least one PPI-statin combination, rhabdomyolysis was reported in 72 cases (Table 6 ). In only one report at least one PPI was considered as a suspected drug and at least one statin was reported as a co-suspected drug. In the 71 cases where PPIs were classified as concomitant drugs, at least one statin was suspected in 67 reports. Beside statins, the drugs most frequently reported as suspected were ezetimibe (five cases, rhabdomyolysis expected) and cyclosporine (four cases, rhabdomyolysis expected only as a consequence of interaction with statins).
In four reports of rhabdomyolysis where neither PPIs nor statins were considered as suspected, the suspected drugs were daptomycin (rhabdomyolysis expected), infliximab (myalgia expected), quetiapine (rhabdomyolysis expected) and oxycodone/naloxone (myalgia, muscle cramps expected). Table 6 displays the crude and adjusted RORs (95% CI) of rhabdomyolysis for the PPIs-statins group and the group of statins no PPIs. In this comparison, the RORs for the PPIs-statins combination were not higher than RORs for statins alone for any comparison. These results were confirmed in the sub-analysis conducted using specific PPIstatin combinations, and specific statins as index groups are displayed in Supplementary Table 13 (see ESM) . Time to 
Discussion
The present study provides the first specific analysis on the potential association of PPIs with muscular toxicity using a method of disproportionality. In the primary analysis, considering the minimum criteria for the detection of a signal by RORs (lower limit of 95% CI [1 and at least three cases reported) [43, 53] , our results showed an SDR for the occurrence of muscular ADRs, related to the overall class of PPIs, rather than any other ADRs associated with PPIs, as compared with non-PPI drugs. Notably, RORs for rhabdomyolysis did not show any SDR. The same was confirmed in the secondary analysis, aimed at evaluating the eventual size of masking effect of statins on the association of PPIs with muscular ADRs. Not surprisingly, the calculated RORs for muscular ADRs markedly increased after the removal of statin-related ADR reports from the dataset. When specific PPIs were considered, only two of the five PPIs (esomeprazole, rabeprazole) were associated with SDRs, whereas all PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole) showed an SDR for muscular ADRs in secondary analysis (i.e. after removing reports of statins as suspect drugs). For rhabdomyolysis, the number of cases for each PPI as index group did not reach the minimum criteria for a significant ROR estimation. The SDR for rhabdomyolysis related to the PPI class was detected only in the tertiary analysis. The latter was an additional explorative analysis conducted to achieve a further unmasking effect including in the index group the PPIs classified regardless of their role (suspected or concomitant drug). This approach should overcome the problem of under-recognition of PPIs as potential causative agents of muscular ADRs. Notably, when the tertiary subanalysis was conducted on single PPIs, a significant ROR for rhabdomyolysis was detected for lansoprazole and omeprazole only. These observations are consistent with the hypothesis that, due to the notoriety bias of statin-related muscular ADRs, the role of non-statin drugs in the occurrence of rhabdomyolysis could often be underestimated by ADR reporters. However, since a causal relationship was not taken into account, these results should be taken with caution and confirmed in other studies. When sensitivity analyses were performed, the covariates 'number of reported drugs' and 'thyroid dysfunction' did not affect the statistical significance of the disproportion in the primary and secondary analyses. On the other hand, when ROR estimations were adjusted for 'number of reported drugs' in the tertiary analysis, the SDR of rhabdomyolysis for PPIs lost its statistical significance. This effect could be related to the different definition of exposure included in the index groups of the tertiary analysis, which made no distinction between suspected and concomitant drugs. For this reason, in cases of rhabdomyolysis where PPIs were frequently reported as concomitant drugs (34/38 reports, 90%), other medications were reported as suspected, and therefore these reports are expected to contain a higher median number of drugs if this represents an under-recognized association.
To the best of our knowledge, the evidence of an association between PPIs and muscular ADRs is currently supported by case reports and case series only [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Although case reports/case series are a powerful tool to highlight unusual side effects to therapy such as rhabdomyolysis related to PPI therapy, a quantitative approach to this safety signal has been poorly explored, despite routine analysis of National Pharmacovigilance databases being performed. Notably, the association between polymyositis and omeprazole was firstly highlighted by the New Zealand Intensive Medicines Monitoring Programme and the UMC in 1997 [54, 55] . However, this signal was poorly investigated [23] , and therefore the risk of muscular ADRs associated with PPI remained unexplored.
The present analysis was based on an approach aimed at unmasking the SDR of PPIs with muscular ADRs upon removal of reports containing statins. Of note, the masking effect has been previously described, along with strategies for its removal [46, 52, 56, 57] . Such removal has been proven to be useful to unravel new signals of public health relevance (e.g. isotretinoin and gastrointestinal haemorrhages, methylprednisolone and cerebrovascular accidents) [56, 57] . Notably, an unmasking strategy was illustrated in the study by Juhlin et al. (2013) [52] , who used statinrelated rhabdomyolysis as an example of a potential masking association. In this retrospective analysis, the use of an unmasking algorithm revealed a potential signal of risk for rhabdomyolysis associated with pantoprazole [52] . Masking can also result when there are a high number of reports of an ADR for a given drug other than the ADR of interest (event competition bias) [58, 59] . This possibility was not explored in the present analysis.
Although the exact mechanism explaining the role of PPIs in muscle injury from a biological standpoint has not yet been understood, various hypotheses have been proposed. Some mechanisms would explain the occurrence of muscular events as a consequence of long-term PPI use, such as the induction of auto-immune antibodies [17, 23] and electrolyte disorders [8, 18, 22, 60, 61] while others would explain the ADRs as occurring after short-term exposure to PPIs, such as non-autoimmune antibody-mediated hypersensitivity reactions [62] . Other proposed mechanisms explain muscular ADRs independently from the duration of use, such as the irreversible inhibition of potassium-hydrogen ATPase in the skeletal muscles [9, 10, 63] and autophagic myopathies [19] . Probably all these mechanisms are not mutually exclusive, and this might explain the variability of the characteristics of the muscular events (e.g. time of onset) observed in our study and in literature [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 23 ]. The overall current knowledge suggests that patients developing muscular toxicity under PPI therapy are likely to carry an individual sensitivity if the PPI is the etiological agent. This contention is in favour of the hypothesis that the mechanism underlying PPI-induced muscular ADRs involves the immune system or results from specific genetic defects [17, 23, 64] .
It is important to consider whether muscular ADRs represent a 'class effect' that applies equally to all members of a class, or whether there are important within-class distinctions. Our tertiary analysis showed a significant SDR for PPIs and rhabdomyolysis when compared with nonstatin drugs, and cases were reported more frequently for lansoprazole and omeprazole. Although the evidence of an association for these drugs is suggested in the literature, especially for omeprazole [8, 9, 12-14, 16, 17, 19, 22] , it could be related to the fact that these PPIs were the first approved in Italy and represent the most-used PPIs [65] . However, this study does not have sufficient power to identify within-class distinctions.
For some PPI-statin combinations, a metabolic interaction can be hypothesized, since PPIs are inhibitors of cytochromes P450 (e.g. CYP2C19, CYP3A4) [66] [67] [68] and P-glycoprotein [69] , of which statins are substrates [28] [29] [30] [31] [70] [71] [72] . Thus, concomitant treatment of PPIs with statins might potentially reduce the metabolism of statins, resulting in a boosted risk of developing severe myopathy and rhabdomyolysis [28] [29] [30] [31] [32] . Inter-individual variability due to genetic polymorphisms (i.e. CYP2C19) may also contribute to the development of these potential drug-drug interactions [31, 68] . Furthermore, assuming that the underlying mechanism of statin-muscular damage could be consistent with the depletion of intracellular cholesterol, with consequent instability of the myocyte cell membrane [66] , PPIs could also be involved in a pharmacodynamic interaction, since PPIs might interfere with cholesterol metabolism with a cholesterol-lowering effect [71, 73, 74] , thus potentiating the cholesterol-related muscular effect of statins. Notably, the only interaction expected between statins and PPIs is that between omeprazole and fluvastatin (fluvastatin label), where it is reported that the concurrent use of fluvastatin and omeprazole may result in increased fluvastatin serum concentrations; however, the clinical relevance of these effects remains unknown [24, 25] .
In our analysis, the hypothesis that an interaction between PPIs and statins may enhance the risk of muscular ADRs, compared with statins alone, could not be confirmed. Notably, in this comparison the RORs of the PPIsstatins group were not higher than those of the statins group, but its value for muscular ADRs showed a fourfold reduction. Considering the explorative nature of our analysis conducted on a spontaneous reporting database, these markedly lower RORs for the PPIs-statins group compared with the statins group cannot be easily ascribed to a possible 'negative interaction', but it could rather be related to undisclosed characteristics of reports included in index and reference groups (e.g. misclassification of a general pain as a muscular pain). Alternatively, given that two myotoxic agents given together should increase the occurrence of myotoxicity even in the absence of a biological or statistical reporting interaction (i.e. expected additive or multiplicative effects, depending on chosen analysis model), another possibility is that the findings with PPIs represent a false positive.
The main strength of our study is the relatively high quality of data used to perform the analysis. Indeed, Italy showed the highest proportion (65%) of well documented reports in a study performed using the WHO global individual case safety report database, VigiBase, from January 2007 to January 2012, using the VigiGrade completeness score to measure the amount of clinically relevant information in structured format [75] . Furthermore, this is the first study attempting to detect and unmask the potential risk of muscular ADRs related to PPIs, excluding the effect of statins, by a method of disproportionality.
Our study also has some limitations. First, a misclassification bias cannot be ruled out, since it is likely that, at least in some reports, concomitant drugs could be more prone to underreporting. In this regard, the most frequent misclassification likely originated from reports that included only a statin, while the patient was actually also taking a PPI, thus reducing the sensitivity of detecting potential interactions. Second, the evidence of a potential relationship between PPIs and rhabdomyolysis rises only in our tertiary analysis, where we did not discriminate between suspected and concomitant drugs. As a consequence, it is more likely in these instances that the reported association of rhabdomyolysis with PPIs or statins is not a causal one, thus being an overestimating influence on the ROR values. In this regard, it is worth noting that rhabdomyolysis is expected for some of the drugs reported as suspected in cases where PPIs were classified as concomitant, even in patients not receiving statins (e.g. bezafibrate, fenofibrate, colchicine, olanzapine, levofloxacin). However, it is important to note that it has been previously demonstrated that including both concomitant and suspected drugs in data mining practices may be a way of detecting some kinds of ADRs earlier, and this might represent an advance in data mining for pharmacovigilance practices [76] . Third, the analysis was performed using the Italian database which contains data of Italian patients only. Therefore, our findings cannot be extrapolated to other populations. Fourth, we decided to exclude poor quality reports, cerivastatin reports, and literature reports from the analysis. This may have introduced a selection bias. A similar situation could have originated from the elimination of duplicated reports by excluding the older ones, which are not necessarily those of lower quality. However, it is unlikely that reports of muscular ADRs excluded for these reasons were distributed differentially between index and reference groups. Fifth, while there are ample and diverse published data on the classification performance characteristics of disproportionate analysis, performance is highly situation-dependent, and we did not include a set of reference negative associations to assess the tendency for false-positive statistical signaling in this context. Sixth, case definition for muscular ADRs included a wide array of terms such as myalgia and muscle weakness that may introduce a noise, like for instance from flu-and flu-like illnesses. This could dilute a signal, but we believe that this effect is likely quite limited, since it would only occur if the noise (i.e. myalgia being flu-and not drug-related) was selective for PPIs. Seventh, we were not able to exclude solicited reports from the analysis. This should have introduced a selection bias. However, to the best of our knowledge, there are no studies that showed that the efficiency of disproportionality methods improves after excluding solicited reports. Therefore, the effect of this bias remains theoretical. Eight, our investigation was performed on data from spontaneous reporting of suspected ADRs, and results are likely affected by the traditional limitations of such studies [77] . These limitations include, but are not limited to, the reduced opportunities for confounder assessment or control. Thus, we must consider potential recorded and unrecorded confounders and effect modifiers that may explain, at least in part, the SDRs observed with PPIs. This required detailed assessment of comorbid illnesses and treatment indications. In other words, there are clinical scenarios that increase the risk of both PPI use and muscle-related adverse events. Many may be envisioned but we discuss a few, the first of which is especially important. We were not able to assess alcohol use as a potentially explanatory/contributory covariate. This is important in evaluating reports of muscular ADRs and rhabdomyolysis in general, since alcohol is possibly the most prevalent myotoxic agent worldwide, but it has particular relevance to the question of whether PPIs cause rhabdomyolysis given the high usage of PPIs by alcoholics. This high utilization of PPIs in the alcoholic population includes both prescribed use for prophylaxis of alcoholic gastritis but also self-medication for a perceived gastritis prophylactic benefit prior to late-night alcohol consumption [78] [79] [80] . Also, PPIs may be administered for gastroprotection in patients receiving corticosteroids, which may cause myopathy and thus be responsible for an innocent bystander effect for PPIs [81] .
Another scenario involves bariatric surgery where patients are at increased risk of rhabdomyolysis and are also often prescribed PPIs for prophylaxis of post-gastric bypass marginal ulceration. Finally, mitochondrial disorders are easily missed/misdiagnosed due to protean clinical manifestations, which may include both muscular ADRs and peptic ulcer disease, providing another confounding pathway between myopathy and PPIs. The latter scenarios are obviously more arcane, given the much smaller patient populations involved, but considering both major and minor potential confounders that can collectively contribute to findings enhances situational awareness of study limitations.
Conclusions
The present study shows a SDR for muscular ADRs related to the overall class of PPIs in the Italian National Network of Pharmacovigilance database. This disproportion was enhanced in the secondary analysis, where the eventual size of masking effect of statins on the association of PPIs with muscular ADRs was confirmed. Notably, in these analyses RORs of rhabdomyolysis did not reach the minimum criteria for the detection of a signal. Only in the tertiary analysis, conducted to achieve a further unmasking effect, did our findings suggest that, disregarding the role of suspected or concomitant drugs, PPIs are included in reports of rhabdomyolysis more frequently than in reports of any other ADRs, when compared with reports not including PPIs or statins. Given the limitations of the tertiary analysis, this result should be confirmed in further investigations. A biological plausibility for most of these ADRs can be hypothesized, even though further studies are needed to elucidate putative mechanisms of PPI-induced muscular injuries. Although muscular ADRs appear to be a class effect of PPIs, it is important to explore the possibility that differences in the risk may occur among PPIs. Our findings need to be replicated using larger multinational databases and different methodologies for assessing disproportion for interaction signal discovery, such as the multivariate analysis and/or use of additive interaction models, that are more sensitive than multiplicative models [82] [83] [84] . For instance, the hypothesis of interaction could be tested by using an additive model to calculate the Omega (X) disproportionality measure for drug-drug-ADR triplets, based on a contrast between the observed and expected number of reports [84] [85] [86] . Finally, our conclusions should be corroborated by robust and well designed observational studies before considering any risk-minimization strategy.
